Objective: The increasing rates of metabolic syndrome and cardiovascular disease in schizophrenia led to investigation into their causes, including atypical antipsychotics and pharmacogenetic variants. This study focused on the peripheral vasculature as a cardiovascular phenotype and the influence of atypical antipsychotics, the aberrant metabolism of nitric oxide caused by endothelial nitric oxide synthetase (eNOS) genetic variants and metabolic syndrome in a cross-sectional sample of schizophrenia subjects. Methods: Associations between eNOS genetic variants and endothelial function was assessed in a cohort of schizophrenia patients taking antipsychotic drugs, whom were undergoing a clinical assessment for endothelial function via the method of peripheral artery tonometry (RH-PAT), as well as metabolic syndrome criteria screening. Analyses were conducted on the entire cohort, then again after stratifying by metabolic syndrome, to investigate the effect of the eNOS variants and metabolic syndrome on endothelial functionality. Results: We included 203 subjects with a mean age of 46 years. The cohort was 36% female, 36% had metabolic syndrome and 85% were currently using atypical antipsychotics. We found associations between the eNOS T -786 C and worse endothelial functioning (lower RH-PAT values) only in schizophrenia patients without metabolic syndrome. Conclusions: Our results suggested that when schizophrenia patients progress to meet metabolic syndrome criteria, the genetic protection of the eNOS T -786 C variant on endothelial function is no longer seen: Other factors of this pro-inflammatory state may be overriding this effect. The results of this study need replication and the factors driving endothelial dysfunction in patients with metabolic syndrome warrant further investigation.
Introduction
The incidences of metabolic syndrome and cardiovascular disease (CVD) in schizophrenia have dramatically increased since the advent of the more commonly prescribed atypical antipsychotics (AAPs) (Hennekens et al., 2005; Laursen et al., 2012; McEvoy et al., 2005) . Explorations into the causes, predictors and interventions; with the goal of ameliorating these side effects in schizophrenia have been numerous and include diet, lifestyle and personalized medication interventions. However, to date there has been little investigation looking at the peripheral vasculature as a cardiovascular phenotype in schizophrenia and the ways atypical antipsychotics, comorbid disease states and genetics play a role in its functioning.
Metabolic syndrome is comprised of metabolic risk factors for Type 2 diabetes and CVD. These risk factors include abdominal obesity, insulin resistance, dyslipidemia and hypertension. Metabolic syndrome increases the risk of CVD and all-cause mortality in schizophrenia and is thought to be associated with a pro-inflammatory state (Ford, 2005; Galassi et al., 2006; Gami et al., 2007; Grundy et al., 2005; Koh et al., 2005; Prossin et al., 2013) .The endothelium is an active biologic interface lining arteries and veins. It regulates growth, tone, hemostasis and inflammation in the circulatory system. Repeated insults to the vascular endothelium result in an inflammatory response and endothelial dysfunction. Dysfunction of the endothelium creates an environment ripe for the development of atherosclerosis and subsequently CVD, and is associated with oxidative stress, an elevation in inflammatory factors and increased inflammatory gene expression (Bonetti et al., 2003; Hein et al., 2009; Kusche-Vihrog et al., 2011; Sena et al., 2013; Venugopal et al., 2002) . Thus, identification of those at higher risk of endothelial dysfunction may help to reduce the risk of CVD, because it is the earliest aberration to be detected in most vascular diseases. There are many contributors to endothelial dysfunction, including lifestyle, diet and medications; but one important contributor is the aberrant metabolism of the anti-inflammatory mediator nitric oxide (Bhanoori, 2011; Boger et al., 1997; Brenol et al., 2010; Da Costa Escobar Piccoli, et al., 2012; Quyyumi et al., 1995) . A reduction in the synthesis and release of nitric oxide is associated with decreased inhibition of platelet aggregation, leading to inflammation, endothelial dysfunction and vascular muscle contraction (Diodati et al., 1998) . Endothelial nitric oxide synthetase (eNOS) is one of the nitric oxide synthetases (NOS) responsible for the production of nitric oxide from L-arginine. Genetic variation within the endothelial nitric oxide synthetase gene (eNOS) may result in impaired endogenous nitric oxide formation and that has been associated with cardiovascular diseases (Metzger et al., 2005; Metzger et al., 2007; Napoli and Ignarro, 2007; Sandrim et al., 2006) . Two commonly studied genetic eNOS variants are: 1. A synonymous single nucleotide polymorphism (SNP) located at the -786 position in the promoter region (T -786 C, rs2070744); and 2. A non-synonymous SNP in exon 7, which results in a glutamine being changed with aspartate (Glu298Asp, rs1799983).
No previous studies have investigated the effect of these two eNOS variants on endothelial functioning in a schizophrenia sample of patients largely exposed to atypical antipsychotics.
Taken together, since AAPs increase the risk of metabolic syndrome and CVD, which, in turn, is associated with a proinflammatory state and a potential increase in endothelial dysfunction due to the pro-inflammatory factors interfering with nitric oxide production in this state, we believe that a pharmacogenetic investigation into the genes controlling nitric oxide production in schizophrenia patients taking AAPs may prove useful in identifying those patients at risk for endothelial dysfunction. Thus, the hypothesis of this candidate gene study was that the impaired nitric oxide production conferred by the eNOS T -786 C and Glu298Asp variants will lead to poorer endothelial functioning in schizophrenia patients, as measured by peripheral artery tonometry. Furthermore, we hypothesized that the aberrant nitric oxide metabolism caused by these polymorphisms would be influenced by the presence of the pro-inflammatory state, metabolic syndrome, due to its association with poor cardiovascular status.
Methods

Subjects
Patients were recruited from mental health clinics within the southeastern Michigan area and considered for inclusion, if they had the following: Patients were excluded if they could not give informed consent, were unwilling to participate or had an active substance abuse or dependence diagnosis; however, nicotine or caffeine users were included. This study was carried out in agreement with the declaration of Helsinki and was approved by the University of Michigan Institutional Review Board.
Clinical assessment
A patient's schizophrenia or schizoaffective diagnosis was confirmed by the Structured Clinical Interview for DSM Diagnoses (SCID), conducted by a trained research assistant and by secondary medical record review. An assessment of current and past medication history, including over-the-counter and herbal medication usage, was completed for each subject. This was also validated by medical record review. A social history, including smoking history, alcohol and drug use was conducted. Study assessments were generally completed in the morning, within 2 hours of the subject's usual waking time. Subjects were asked to fast for at least 8 hours prior to coming in. All assessments were completed at this single visit. Vital signs, body mass index (BMI) and hip/waist measurements were taken for each patient. Blood samples were drawn for genetic and fasting metabolic assessments, including: homocysteine, glucose, insulin, HbA1C and a complete lipid panel (total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL)). The National Cholesterol Education Program's Adult Treatment Panel III (NCEP/ATP III-a) (Grundy et al., 2005; National Cholesterol Education Program Expert Panel, 2002) criteria were used to diagnose metabolic syndrome for each patient, if they had three or more of the following:
(a) Waistline ≥ 40 inches (men) or ≥ 35 inches (women); (b) Blood pressure ≥ 130/85 or currently being treated for hypertension; (c) triglycerides >150mg/dL; (d) HDL < 50mg/dL (men) or < 40mg/dL (women) or currently being treated for abnormal lipids; and (e) fasting blood glucose ≥100mg/dL or currently being treated for elevated blood glucose.
Finally, we assessed physical activity based on a previously designed questionnaire (Orrell et al., 2007) which was validated in a population with coronary heart disease, using RT3 triaxial accelerometer measurements. For this assessment, participants were asked about their total amount of time (in minutes/week during the week immediately preceding the study visit in which DNA was obtained) they spent engaging in strenuous activity (e.g. jogging, aerobics), moderate activity (e.g. housework, light jogging, painting and so on) and mild activity (e.g. walking). A "Total Activity Score" (in a metabolic equivalent of task (MET) per min) was computed by multiplying the time for each activity (in min) by a metabolic equivalent score (i.e. 3, 5 or 7 METs).
Endothelial function assessment
We assessed endothelial function using the peripheral artery tonometry (RH-PAT) method, with the EndoPat 2000 device (Itamar Medical, Caesarea, Israel). Briefly, this assessment requires patients to sit still for a minimum of 15 minutes, with a digital probe on each index finger and a blood pressure cuff on their non-dominant arm. The assessment is broken up evenly into three periods (e.g. three 5-minute periods) and for the middle period, the cuff is filled with a pressure of 200 mmHg or 60 mmHg above the subject's blood pressure. The RH-PAT values are calculated using the algorithm provided by the Endo-Pat 2000 software. The RH-PAT value is a calculation of the post-topre occlusion endopat signal in the occluded arm, compared to the same ratio in the control arm, and is controlled for baseline vascular tone. This clinically useful method of measuring endothelial-dependent vasodilation is shown to be reflective of nitric oxide bioavailability. It was validated and previously described within several populations (Bonetti et al., 2004; Ellingrod et al., 2011; Rubinshtein et al., 2010) .
Genetic analysis
DNA was extracted from whole blood samples using the salt precipitation method (Lahiri and Nurnberger, 1991) . We completed genotyping for both the eNOS T -786 C (DBSNP rs2070744) and Glu298Asp (DBSNP rs1799983) polymorphisms using pyrosequencing methods (Marsh et al., 2005) . The pyrosequencing primers were designed using Pyromark Assay Design Software, Version 2.0 (Qiagen Group, USA). Specific conditions for each variant's assay are available upon request.
Statistical analysis
Subjects were considered AAP users if they were currently taking olanzapine, clozapine, quetiapine, risperidone, iloperidone, paliperidone, ziprasidone or aripiprazole. Furthermore, the antipsychotics were broken down into groups, based on their propensity to cause metabolic side effects (Table 1) . Cumulative chlorpromazine equivalents (CPZE) were standardized by converting dosage regimens to chlorpromazine equivalents, based on a mg/kg basis, then adding those equivalents together if antipsychotic polypharmacy was present (Andreasen et al., 2010) . In order to determine any baseline differences based on genotype, student t-tests were used to compare the mean values of demographic characteristics and chi-squared analysis was used to compare dichotomous variables. To assess the association between each eNOS genotype and RH-PAT values, analysis of variance (ANOVA) and regression analysis were conducted on the entire schizophrenia sample. The same type of analyses were conducted after stratifying the sample by presence or absence of metabolic syndrome. The regression analyses used the RH-PAT index as the dependent variable and antipsychotic exposure (cumulative CPZE), smoking and race as independent variables, as these differed by genotype or affected RH-PAT values (detailed in the results in Table 1 , below). All analyses were conducted using the JMP 9.0 statistical program. A p-value < 0.05 with a 95% CI was considered significant for this study.
Results
Demographic analysis
Our study population included 203 males and females with schizophrenia (59.1%) or schizoaffective disorder (40.9%). The average age of our sample was 46.0 ± 11.5 years. Approximately 36% were female, 56.7% white and 35.5% African American, which was a natural reflection of the recruitment area. The rest of the study population was American Indian, Asian, Hispanic or Latino. A large majority of the sample used AAPs (85.7%), while the rest used one of the following first-generation antipsychotics: haloperidol, fluphenazine, perphenazine or trifluoperazine. Our population's rate of metabolic syndrome (36.5%) is similar to that of other studies Meyer et al., 2005) ; and of note, their Total Activity Scores did not differ based on metabolic syndrome stratification (p = 0.2). The eNOS T -786 C and Glu298Asp variants were determined to be in Hardy-Weinberg equilibrium (both p > 0.09) and not in linkage disequilibrium (D'= 0.471), using Haploview Version 4.2. We were unable to genotype five participants for the eNOS T -786 C variant and six participants for the eNOS Glu298Asp variant, due to sample fatigue. For the study population demographics, as well as demographics stratified by metabolic syndrome, see Table 1 .
Genotype group comparisons
Preliminary analyses to identify differences based on genotype showed one difference. Both variants had significant differences when looking at race (both p < 0.001). The eNOS T -786 C polymorphism had no African-Americans with the CC genotype and the eNOS Glu298Asp had two African-Americans with the AspAsp genotype. Table 2 has a breakdown of each variant by race.
RH-PAT and demographic variables
Similar to our previous work looking at the variables affecting the RH-PAT index; we found that age, race, gender, cumulative CPZE, AAP use or smoking status did not significantly affect endothelial function (smoking status p = 0.07 and all others, p > 0.15). When stratifying by presence of NCEP/ATP III-a metabolic syndrome, it was found that the RH-PAT index was significantly affected by smoking status (F(1,115) = 5.12; p = 0.02) and cumulative CPZE (F(1,110) = 5.77; p = 0.01), only in those subjects without metabolic syndrome. Finally, RH-PAT did not differ by Total Activity Score prior to nor after stratifying by metabolic syndrome (p > 0.7 for all).
Genotype and RH-PAT
We sought to determine the overall pharmacogenetic effect of the eNOS variants on RH-PAT index within our collective schizophrenia cohort. Both variants showed no significant association with RH-PAT index (T -786 C: F(2,177) = 2.3; p = 0.1 and Glu298Asp: F(2,176) = 1.72; p = 0.2), when looking at the group as a whole. The eNOS T -786 C variant showed a trend (Cohen's effect size d = 0.5) for the CC genotype to have a higher RH-PAT ± SE (2.03 ± 0.13), versus the TT genotype (RH-PAT ± SE = 1.75 ± 0.06), which may be of clinical significance, as a value of 1.67 is identified as a threshold for meeting criteria for endothelial dysfunction (Bonetti et al., 2004) . Next, we stratified our sample by presence of NCEP/ATP III-a metabolic syndrome. We found a significant correlation of RH-PAT index with the eNOS T -786 C variant in those participants without metabolic syndrome, where the CC genotype had a mean ± SE RH-PAT of 2.17 ± 0.163 and the TT genotype had a mean ± SE RH-PAT of 1.71 ± 0.069 (F(2,113) = 3.41; p = 0.03, Cohen's effect size d = 0.8). In those participants with metabolic syndrome, the RH-PAT and T -786 C correlation was not present (F(63,2) = 0.057; p = 0.9). There were no significant associations between RH-PAT and the Glu298Asp polymorphism for either the participants with or without metabolic syndrome (p = 0.6 and p = 0.3, respectively). Table 3 and Figure 1 show comparisons of RH-PAT index and endothelial dysfunction, based on the eNOS T -786 C variant and presence of metabolic syndrome. Given the effect of antipsychotic exposure (cumulative CPZE) and smoking status on endothelial function (Alian et al., 2012; Guo et al., 2009) , as well as the racial differences seen in the variants within our sample (Tanus-Santos et al., 2001) , we performed a regression analysis where RH-PAT was the dependent variable and the cumulative CPZE, race, smoking status and eNOS genotype were the independent variables. Our regression analysis on the collective schizophrenia cohort (regardless of metabolic syndrome diagnosis) yielded no significant association Figure 1 depicts the eNOS T -786 C variant and its association with endothelial function, as measured by RH-PAT index. For schizophrenia subjects without metabolic syndrome, the CC genotype demonstrates superior endothelial functioning measurements, as compared to the aberrant metabolism induced by the TT genotype; however, when looking at the individuals with schizophrenia whom have metabolic syndrome, the endothelial function is overall poorer and does not differ based on the eNOS T -786 C variant, thus suggesting the genetic protection of the CC genotype was lost. eNOS: Endothelial nitric oxide synthetase; RH-PAT: peripheral artery tonometry.
with RH-PAT index (both > 0.2); however, when stratifying by the presence of metabolic syndrome, our regression showed a significant association where the eNOS T -786 C variant (F = 3.65; p = 0.02) and smoking status (F = 6.03; p = 0.01) for those without metabolic syndrome contributed to the significance of the whole model (F(6,108) = 3.39; p = 0.004). In contrast, the same regression model in those with metabolic syndrome was not significant (F(6,62) = 0.50; p = 0.8). When using the same model above to look at the eNOS Glu298Asp variant, the model was found significant (F(6,106) = 2.50; p = 0.02) in those patients without metabolic syndrome, due to the effect of smoking (F = 4.10; p = 0.04) and cumulative CPZE (F = 4.81; p = 0.03), but not genotype (F = 0.9; p = 0.4).The regression analysis was nonsignificant, when looking at the Glu298Asp variant in schizophrenia patients with metabolic syndrome (F(6,63) = 0.5; p = 0.8).
Discussion
Overall, approximately 48% of our study population met the criteria for endothelial dysfunction (RH-PAT < 1.67), as seen in Table 1 ( Bonetti et al., 2003) . Given the known adverse effects of metabolic syndrome on the cardiovascular system (Ingelsson et al., 2007) , it is noteworthy that those meeting metabolic syndrome criteria did not have a significantly higher percentage meeting the endothelial dysfunction criteria, compared to those without metabolic syndrome (49% versus 47%, p = 0.8), nor was there a significant difference found in RH-PAT values (p = 0.9). This finding did not take either of the eNOS variants into account; however, when segregating our schizophrenia subjects based on the presence of metabolic syndrome, we did reveal variables that influence the RH-PAT index, including cumulative CPZE and smoking status, in our subjects without metabolic syndrome. Both smoking status and atypical antipsychotic use (which a majority of our subjects were on) are known risk factors for cardiovascular side effects (Grassi et al., 2010; Puranik and Celermajer, 2003) , but it appeared that these factors do not play a significant role in endothelial functionality in schizophrenia patients who progress to meet metabolic syndrome criteria. Furthermore, our regression analyses found that our study participants with schizophrenia who do not have metabolic syndrome had significantly worse RH-PAT values if they carried the TT genotype of the eNOS T -786 C variant, which contradicted a study in healthy subjects using brachial artery function as a predictor of endothelial function (Imamura et al., 2008) ; however, this study did not directly report the rate of metabolic syndrome in their population. Taking our results together, we found that once metabolic syndrome is present, the adverse effects on the cardiovascular system may be creating a state where endothelial dysfunction in schizophrenia is not significantly affected by smoking, CPZE status nor eNOS genotype. A possible explanation for this occurrence could be the pro-inflammatory state created by metabolic syndrome and its associated insulin resistance, which is driving the endothelial dysfunction and overriding any genetic protection with the eNOS variants' production of nitric oxide (Leonard et al., 2012) . Previous studies correlate elevation in inflammatory markers with metabolic syndrome in various populations (Grundy et al., 2005; Koh et al., 2005; Lee et al., 2000; Prossin et al., 2013) . Indeed, there were expected differences, when comparing the schizophrenia participants with metabolic syndrome and those without metabolic syndrome. Specifically, there were differences in either the criteria that defines metabolic syndrome (e.g. triglycerides, BMI, fasting glucose) or known factors that increase the risk of getting metabolic syndrome, like age, sex and type of antipsychotic currently being taken. The culmination of these various differences within these two groups creates the distinct metabolic syndrome phenotype that exposes certain variables like smoking, cumulative CPZE and genotype, that influence the RH-PAT index when it is not present and overrides these variables' influence on RH-PAT index when it is present. It may be possible that the eNOS -786 CC variant of nitric oxide, a gaseous anti-inflammatory mediator of the inflammatory cascade, is only able to preserve endothelial functioning in schizophrenia patients that are not subject to the pro-inflammatory factors associated with metabolic syndrome; however, when schizophrenia patients progress to metabolic syndrome, the endothelial function is no longer responsive to the genetic protection of nitric oxide variants investigated in this study, but rather the inflammatory cascade that results from this syndrome. This theory could be a future line of research in endothelial dysfunction in schizophrenia.
The RH-PAT-genotype differences seen between those with and without metabolic syndrome may be a result of the adequate treatment of the individual criteria of metabolic syndrome (insulin resistance, lipid abnormalities, etc.) as there is a line of research purporting the anti-inflammatory effects of hydroxymethylglutaryl CoA reductase inhibitors (statins) (Antonopoulos et al., 2012; Balakumar et al., 2012) . As would be expected, the use of statins was more prevalent in the group with metabolic syndrome than those without (55% versus 12%, respectively); however, RH-PAT values were not influenced by statin use (p = 0.6). Given that many schizophrenia patients taking AAPs progress to metabolic syndrome, the factors that are influencing endothelial dysfunction in these patients does warrant further investigation. The findings in this study add to the plethora of research showing the detrimental consequences of atypical antipsychotic-associated metabolic syndrome and the need to find personalized medicine or alternate interventions, in order to prevent and lessen this comorbidity in the schizophrenia population.
Our study is not the first to find associations with eNOS variants and a cardiovascular phenotype that depended on the presence of metabolic syndrome. A study by Pons et al. (2009) looking at restenosis in patients that underwent percutaneous coronary intervention found an opposite interaction between metabolic syndrome and eNOS variants: They discovered higher rates of clinical restenosis that varied depending on the eNOS variant, in patients with metabolic syndrome only, while the variants did not have a significant effect on clinical restenosis in patients without metabolic syndrome. This study used the patient population from the Genetic Determinants of Restenosis (GENDER) study (Agema et al., 2004) , which only takes cardiovascular and lipid-lowering medications into account, but does not account for any other medications that may affect metabolic syndrome rates like AAPs, making direct comparisons to our unique population difficult.
Within mental illness, there was one other study looking at peripheral arteriole endothelial-dependent vasodilation in unmedicated schizophrenia patients and controls (Israel et al., 2011) . This study did not have a genetic component and used a different measure of endothelial function, laser Doppler flowmetry (LDF); therefore, their brachial measurement results cannot be compared to our digital measurements, as both provide distinct information (Hamburg et al., 2011) . Nevertheless, this group found evidence of peripheral endothelial dysfunction in patients with acute schizophrenia not yet treated with medications, as compared to healthy controls. Given the link between endothelial dysfunction in both unmedicated and medicated schizophrenia patients found in studies completed to date, future prospective studies investigating the link between endothelial dysfunction and cardiovascular events are needed. An emphasis on assessing additive endothelial dysfunction risk, if any, on treating schizophrenia patients with AAPs should also be investigated.
There are a few limitations that need to be addressed when interpreting the results of our study. This study was cross-sectional in nature, with a limited sample size, and therefore the results need to be repeated in separate, prospective samples to confirm the effects of the eNOS polymorphisms on endothelial function in schizophrenia. It would also be highly useful to correlate results with a measure of nitric oxide and inflammatory mediators, such as C-reactive protein or an interleukin; however, as so far studies show correlations between endothelial dysfunction and elevations in inflammatory factor levels and inflammatory gene expression (Hein et al., 2009; Kusche-Vihrog et al., 2011; Sena et al., 2013; Venugopal et al., 2002) . We did not investigate another common variant of the eNOS gene called intron 4a4b VNTR, and so associations between this variant and endothelial functioning cannot be ruled out. Our study also had multiple comparisons which we did not control for, but given the significance of our main, hypothesis-driven finding, a more stringent p-value cutoff (e.g. p < 0.01) could be applied. Our cohort included a wide age range, and age is shown to effect endothelial function (Celermajer et al., 1994; Egashira et al., 1993) ; however, we did not control for age in our regression analysis, because within our sample there was no difference in RH-PAT values based on age (p = 0.9) and our cohort's age range was relatively narrow (46.0 ± 11.5 years). Finally, although we looked at a population mainly taking metabolically adverse AAPs, polypharmacy was common among the entire cohort.
Conclusion
This investigation found an association between the eNOS T -786 C variant and endothelial functioning in a population of schizophrenia patients taking AAPs whom did not meet criteria for metabolic syndrome; however, this association was lost once the criteria for metabolic syndrome was met. Our findings suggest that schizophrenia patients may lose the genetic protection conferred by the anti-inflammatory mediator nitric oxide on endothelial function measurements, once they progress to the pro-inflammatory state of metabolic syndrome; however, our findings cannot be extended to show that the eNOS gene is a risk factor for metabolic syndrome itself. These findings add further evidence to the need to find personalized medicine interventions to quell the metabolic side effects of commonly used AAPs and to preserve any genetic protection these patients may have. One possible line of research, given the findings of our candidate-gene study, could be L-arginine supplementation based on eNOS genotypes. Finally, future pharmacogenetic studies may need to take metabolic syndrome into account when investigating the associations between a given cardiovascular phenotype and a gene variant.
